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Summary 
The present report is divided into three parts. Part I describes the 
identification and characterization of a previously unidentified jacalin-
bound protein (JBP), human serum alpha2-HS glycoprotein (0C2HSG). 
With the advent of this finding, we further investigated the applications 
of jacalin in the study of 0C2HSG as shown in part II. Finally, part HI 
describes the use of jacalin in studying the pathogenesis of IgA 
nephropathy. 
We have recently adopted immobilized-jacalin as an affinity 
adsorbent to purify human serum IgA for laboratory study. In the course 
of our investigation, we have detected a protein that co-eluted with IgA 
from the jacalin-agarose affinity column. This protein is an a-globulin of 
molecular weight 55 kDa as demonstrated by immuno-electrophoresis and 
SDS-PAGE. It constitutes a significant portion (24.0±0.9%, N=s30) of 
total jacalin-bound protein (JBP). This 55 kDa protein was identified and 
was subsequently confirnled to be azHSG. The molecular interaction of 
a2HSG with jacalin was characterized by competitive ELISA. Human 
serum IgA, human colostrum secretory IgA (slgA), and monosaccharides 
including D-galactose or melibiose, exhibited strong inhibitory effect on 
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its binding to jacalin. Furthermore, the jacalin purified by IgA-Sepharose 4B 
affinity column also strongly inhibited the binding of biotinylated-jacalin to 
OC2HSG. Accordingly, we propose that 0C2HSG binds in a similar manner as that 
of the bovine fetuin or human IgA to jacalin. Based on these findings, we 
suggest two potential applications of jacalin in the study of 0C2HSG as described 
in part II. Firstly, Purification of 0C2HSG can be achieved by combining 
jacalin-agarose affinity column and gel filtration. By using this method, about 
2 mg of highly purified and immunoreactive 0C2HSG can be obtained within 8 
hours from 6 ml of serum giving a yield of 46%. This method was effective for 
purification of 0C2HSG from either serum or plasma. Preliminary evaluation of 
the factors affecting the yield of a^HSG from jacalin-Sepharose affinity 
column suggested that increasing the serum dilution will increase the recovery 
of 0C2HSG，but the removal of serum albumin did not improve the yield of 
a2HSG. Secondly, we developed a novel ELISA by using anti-human a2HSG . 
antiserum as capturing antibody with labelled jacalin as detecting antibody for 
detection of a2HSG. The sensitivity of this ELISA in detecting a2HSG was 
shown to be 1 ng/ml and linearity was obtained between 1 and 250 ng/ml. The 
ELISA is highly specific and detects only the human a2HSG but not its 
counterpart, the fetuin, from the sera of mouse, rabbit or fetal bovine. 
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Serum proteins including human IgA, human serum albumin (HSA), 
human IgG, bovine serum albumin (BSA) did not interfere the detection 
of a2HSG. 
In part HI, we aimed to measure (1) the distribution of monomelic 
IgA (mlgA) and polymeric IgA (plgA) in the sera of IgAN patients, (2) 
the kappa and lambda ratios of the mlgAl and plgAl of IgAN patients, 
and (3) the presence of IgA immune complexes in the sera of IgAN 
patients. By combining the jacalin-agarose affinity chromatography 
followed by FPLC fractionation of JBP，mlgA was well separated from 
plgA. As the FPLC fractions were analyzed with ELISA, secretory IgA 
and most of the IgA immune complexes (IgA-IC) (IgA-fibronectin，IgA-
C3，IgA-IgG, and IgA-IgM) were shown to distribute exclusively in 
fractions 30 to 40 (pooled-Pl), and the mlgA was distributed from 
fraction 41 to 50 (pooled-P2). We demonstrated that patients with IgAN 
display a high serum level of IgA, compared with controls, in both mlgA 
and plgA fractions. Nevertheless, IgA-IC including IgA-fibronectin, 
IgA-IgG, IgA-C3, and secretory IgA were not elevated in IgAN patients 
as compared with the controls. The kappa to lambda (k/X) ratio of both 
mlgAl and plgAlwere reversed significantly in IgAN patients when 
compared with controls (P<0.01). Hence, we suggest that the bone 
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marrow may play an important role in the long term overproduction of 
circulating IgA in IgAN. 
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1.1 Jackfruit and jacalin 
Genus Artocarpus (from Gk arto, bread, and karpos, fruit, 
referring to the starchy fruit) contains some 50 species of evergreen or 
deciduous, monoecious, latex-bearing plant. Jackfruit is the fruit of A. 
heterphyllus Lam. according to Linnaeus's classification system, while 
A. integrifolius L.f and A. integrifolia are its synonyms (1, 2). This is a 
fruit tree of the humid tropical region where it is cultivated primarily for 
fruit and ornamental interest, but also used as agricultural shade for 
coffee and as living supports for peppers. It is a very ancient cultivation 
in India and appears to have been taken early by the Arabs to the East 
African coast. It has now spread throughout the tropics and is found in 
abundance in Brasil and southern East Asia such as Malaysia, 
Philippines, Indonesia, and Thailand. 
Jackfruit is one of the biggest fruits in the plant world. The fruit 
hangs from the main stem of size 30-90 x 25-50 cm and weighing up to 
30 kg, and fruits weighing 50 kg having been recorded. Moreover, up to 
250 fruits per tree are produced per annum. Seeds are large, oblong, 
about 3 x 2 cm, and more than 150 seeds can be recovered from a 
medium size jackfruit (3). 
Lectins have been defined as sugar-binding proteins or 
glycoproteins of non-immune origin which agglutinate cells and precipi-
tate glycoconjugates (4). Lectins are devoid of enzymatic activity towards 
sugars to which they bind (5). Jacalin is the lectin extracted from the 
seeds of A. integrifolius • However, the term ‘jacalin，may be informally 
used to describe lectins from other Artocarpus species such as A. 
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champeden and A. tonkinensis (6). In the present report, jacalin is 
referred to lectin from seeds of A. integrifolius. 
1.2 Biochemical and immunological properties of jacalin 
Recent interest in the study of jacalin focuses mainly on the 
molecular structure, peptide sequence, and the reactive sites in the jacalin 
by which they interact with other proteins. 
1.2.1 Molecular Weight of Jacalin 
A few laboratories using low-pressure gel-permeation chromatogra-
phy on Sephadex G-100 have reported that jacalin has a molecular mass 
varying between 36-54 kDa (7，8，9, 10，11). However, these values are 
inconsistent with those derived from analytical-ultracentrifugation (65 
kDa) (12) and from Ferguson-plot analysis (66士 1.2 kDa) (13). 
1.2.2 Molecular structure of jacalin 
Preliminary analysis of jacalin structure by Appukuttan and Basu 
(10) has suggested that native jacalin behaves as a homotetramer of 
identical noncovalently associated 10 kDa subunits by using gel filtration 
under 6 M guanidine hydrochoride (10). However, recent findings altered 
this view by suggesting that jacalin contains two types of polypeptides: a-
chain (heavy chain) (12-15 kDa) and P-chains (light chain) (2.1 kDa) (12， 
14，15，16). The a-chain has two sub-types: a (12 kDa) and a' (15 kDa )， 
and microsequencing of (3-chain unravells three forms : (31，p2, and p3 of 
20 amino acids long (12，15, 17). The amino acid sequence of a- and 
oc，-chain demonstrated 95% homology except a valine for 
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isoleucine interchange at position 113, while at positions 31 and 66 in a-
and a'-chains respectively contain an alternative hydrophobic amino acid 
(Val/Ile and Met/Val respectively) and that in position 45 of the a'-chain 
has threonine or lysine. “ Although both chains are glycosylated, the 
extent of glycosylation in the a'-chain is greater than that of the a-chain. 
Furthermore, a，- and a -chain exhibit an approximate ratio of 1:3 by 
SDS-PAGE (12). • 
According to the data derived from SDS-PAGE, gel filtration and 
peptide sequence of jacalin, the quaternary structure of native jacalin is 
suggested to be tetrameric. This opinion is supported by the presence of 
four symmetrical globulins per jacalin molecule by negative-staining 
electron microscopy (12). Such tetrameric structure may consist of three 
a-chains each non-covalently associated with one a，一chain (15) and the 
three (3-chains are each non-covalently attached to the a-chains to give 
an a3 p3 trimer (14). This suggestion is further supported by the fact that 
a- and p-chains are shown to be the cleavage products from a 17 kDa 
precursor (6)，and data derived from cloning of jacalin also suggested 
that the 17 kDa precursor is in turn the cleavage product of a 24 kDa 
prepropeptide (18). Accordingly, the most likely combination of the a-
and p-subunits in the jacalin is (ap)3 (a'(3) (14)，from which the molecu-
lar weight is calculated as 59.4 kDa. On the other hand, attempts to 
determine the three-dimensional structure of jacalin by X-ray crystallo-
graphy also demonstrated a rather heterogeneous estimation on this issue 
(13，19，20) and hence the exact composition in the quaternary structure 
of jacalin is still uncertain. 
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1.2.3 Specificity of jacalin to Thomsen-Fredenreich-antigen (T-antigen) 
Jacalin was known to specifically recognize T-antigen [D-
Galp(l ~>3)D-GalNAca( 1 ->0)Ser/Thr] (Fig.l) (8，21’ 22) which is a 
tumour-associated antigen of non-oncofetal origin that probably one of 
the few chemically well-defined antigens with a proven link to malig-
nancy (23). The binding is highly specific as jacalin does not bind to 
conformationally related disaccharides such as lactose, N-acetyl-
lactosamine or D-Gal p(l->3)D-GlcNAc (21). Moreover, it only 
recognizes the D-Gal|3(1^3)D-GalNAcal but not its anomer D-
Gaip(l->3)D-GalNAc|31 (22) and this property make it a highly 
discriminating probe for studying T-antigen. 
The thermodynamic parameters for the binding of mono-
saccharides suggest that the -OH groups at C-2, C-3, C-4, and C-6 in 
the D-galactose configuration are important loci for interaction with the 
jacalin (11，21). This viewpoint is partially supported by a recent report 
using quantitative precipitin-inhibition assay with various haptens (8). 
The finding revealed that the -OCH2- group at C-l and -OH groups at 
C-4 and partially at C-6 in the a-glycoside of D-galactose configuration 
are important for jacalin-sugar interaction. 
、 1.2.4 The internal repeated sequence in the jacalin 
Analyses of the heavy chain (a) sequence showed the presence 
of an internal repeat spanning residues 7-64 and 76-130 with an identity 
of 25.4% (17). This repeated sequence was found to be statistically 
significant by the program IALIGN and the result suggested that the 
probability of obtaining such a similar repeat by chance alon| is less 
than 1 in 106. The possible role of the internal repeat is that they 
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Fig.l Thomsen-Friedenreich antigen (T-antigen) 
(D-Gal|3(l-3)D-GalNAca(l-0)Ser/Thr). Modified from 
Ahmed H, Chatterjee BP (8). The arrows indicate the reactive 
loci for jacalin binding. 
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function as the sugar binding site although the exact binding site(s) per 
repeat is still unknown (17). In fact, a 4 kDa fragment, spanning from 
residue 68 to 109 of jacalin, is shown to possess IgA-binding property by 
the limited proteolysis of jacalin (9). This 4 kDa fragment more or less 
overlaps with one of the internal repeat region and this again suggests the 
existence of carbohydrate binding site within the repeat region of jacalin. 
Nevertheless, the two internal repeat regions, which span over 92% of 
the sequence (17)，are likely to encompass the active-site residues. 
Hence, these sequences are important structural features and are possibly 
of direct relevance to their carbohydrate binding. 
1.2.5 Jacalin-Bound Proteins (JBP) 
Human serum IgA was one of the earliest protein known to 
interact with jacalin (24) but not mouse IgA or rat IgA (62). Although 
jacalin was shown to bind both monomeric IgA (mlgA) and secretory 
IgA (slgA) (25), the binding was found to be restricted to IgAl but not 
IgA2 (26, 27, 62). However, the latter issue is contested as other authors 
have demonstrated that jacalin binds IgA2 of both allotypes (25, 28). 
Although most investigators agree that jacalin has a higher affinity for 
IgAl subclass, the binding between jacalin and IgA2 is yet controversial 
and this may pose a potential risk of using jacalin for separation of IgAl 
from IgA2 (see section 1.3). Human Cl-inhibitor (Cl-INH) (29), human 
serum albumin (HSA) (30), and IgD(7，31) were also demonstrated to 
bind jacalin. 
1.2.6 Interaction of jacalin to JBP 
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IgAl contains 13 amino acids and four acetylgalactosamines in the 
hinge region which is not found in IgA2 (64). In the hinge region, IgAl 
has a characteristic grouping of five o-glycosidically linked 
oligosaccharides. Four of these are D-Gal(3(1 -^3)D-GalNAca( 1 
which is exactly matched to the sequence of T-antigen (see 1.2.3). This 
makes IgAl binds with high affinity to jacalin (31，32，62). IgD has a 
hinge region similar to IgAl with respect to carbohydrate moiety and 
jacalin interacts with IgD (31). Neither IgM, IgG nor IgE interacts with 
jacalin because of absence of the specific carbohydrate moiety (7，11，24， 
28，31，65). A variety of other glycoproteins including Cl-INH, chorionic 
gonadotropin, plasminogen, bovine protein Z, bovine coagulation factor 
X and fetuin, known to contain the typical O-linked oligosaccharides, has 
also been shown to interact with jacalin (22). In fact, some JBP of a-
mobility remain unidentified (7). 
1.2.7 Immunological properties of jacalin 
The crude extract of jackfruit has long been known to exhibit an 
exquisitely sensMve agglutinating property for erythrocytes from 
numerous species (human, sheep, rat, mouse, hamster, rabbit, chicken, 
etc.) (33)，and the reactive component that mediates the agglutination is 
• the jackfruit-agglutinin (jacalin). Jacalin mediates phagocytosis of type 
II group B Streptococci via receptors that are not dependent on divalent 
cations and that are not modulated by plating monocytes on antigen-
antibody complexes (50). 
Jacalin has attracted much interest with regard to its potent and 
• selective mitogenic effects on distinct T- and B-cell functions. Bunn-
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Moreno et al. (33) first reported that crude jacalin extract elicited 
powerful mitogenic ability for unfractionated peripheral blood 
mononuclear cells (PBMC) and purified T lymphocytes. Interestingly, it 
caused potent polyclonal activation of these cells as measured by reverse 
haemolytic plaque assay (33). In contrast, jacalin inhibited human B 
cells differentiation by both a direct effect and activating T-suppressor 
cells (65). 
1.3 Application of jacalin in medical research 
Jacalin has been used as a probe to detect the T-antigen in human 
carcinoma (22). As the commonly used peanut agglutinin and anti-(T-
antigen) monoclonal antibodies are not very specific in detecting this 
antigen (22), the specificity of jacalin to T-antigen make it a highly 
discriminating and easily available probe for studying the expression of 
T-antigen on cell surface, which may be of enormous potential in cancer 
research. 
It is due to the high affinity binding between IgAl and jacalin, that 
immobilized-jacalin is used for affinity purification of serum IgA (25, 
62) or separation of IgAl from IgA2 (62，26). It should be pointed out 
that there are discrepancies in the literature as to the binding of IgA2 to 
jacalin so that the affinity purified IgAl samples may not be free of 
IgA2. 
In a recent report, jacalin was shown to inhibit the infection by 
human immunodeficiency virus (HIV) (34). The inhibition was demon-
strated to involve a 14-amino acid sequence of jacalin a-chain, which is 
analogous with a peptide of the second conserved domain of HIV gpl20. 
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The anti-HIV effect was confirmed by a synthetic peptide corresponding 
to this similar stretch (34). These data suggest that jacalin has potential 
therapeutic value for acquired immunodeficiency syndrome. 
1.4 Background knowledge of 0C2HSG 
0C2HSG was first identified as a normal human serum protein and 
named a2-Z-globulin in 1960 by Heremans (35)，and subsequently 
described in detail by Schmid and Bii rgi under the name 
Ba-oc2-glycoproteins (35). It was called alpha2-HS glycoprotein in 
honours of these workers. The 0C2HSG has a molecular weight of 50-56 
kDa on SDS-PAGE (36) and is present in normal plasma at a concentra-
tion of 600 mg/1 (37). Its chemical composition and physico-chemical 
properties are well described (36, 38，39, 40, 41，42). It is known to be 
synthesized by the liver (63). It is one of the few known negative acute-
phase protein and its plasma levels had been shown to fall significantly 
during different inflammatory process (37，145). In vitro studies showed 
that monocyte-conditioned medium, recombinant human IL-6 and IL-1 
act as down-regulatory factors to its synthesis by human hepatoma 
HepG2 cells (43)，but the mechanism of its inflammatory-induced down-
regulation is not yet elucidated. Indeed, the serum level of 0C2HSG is 
significantly reduced in patients with acute lymphocytic, acute 
nonlymphocytic, chronic granulocytic and chronic myelomonocytic 
leukemias, Hodgkin's and non- Hodgkin's lymphomas, myelofibrosis, 
and multiple myeloma (44). 
0C2HSG had also been shown to mediate immunological function. 
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It acted as an opsonin in mediating the phagocytic properties of human 
neutrophils (45) and monocytes in vitro (46，47). Malone et al. (35) al*so 
demonstrated that 0C2HSG acts as a chemotoxin for monocyte (35). 
One of the well known features of 0C2HSG is that it is concentrated 
preferentially in calcified tissues (e.g. bone and teeth) when compared to 
other serum proteins (100-fold greater than albumin). Some reports have 
demonstrated that 0C2HSG plays an important role in the bone metab-
olism (47，48，147) as serum 0C2HSG levels have been shown to fall 
significantly in different bone diseases: such as osteogenesis imperfecta 
and Paget's disease while its concentration in the diseased-bone tissues 
is highly elevated (48)， suggesting a role in increasing bone turnover 
(49，147). 
Some reports have suggested that 0C2HSG is the human counterpart 
of fetuin of other species. Functionally, human 0C2HSG may play a role 
in developing tissues, especially in the human fetus (146). Structurally, 
the sequence of fetuin shows over 70% similarity to human 0C2HSG and 
both proteins have the same arrangement of disulfide loops (53). 
Nevertheless, comparison of N-glycosides of fetuins from different 
species and human 0C2HSG shows a species-specific presence of such 
carbohydrate side chains (144). 
So far, the exact biological and physiological function of 0C2HSG 
is not well delineated and it still belongs to the group of serum proteins in 
search of functions. 
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Chapter 2 
Materials and Methods 
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2.1 Design of the experiment 
Jacalin is known to bind strongly to human serum IgA, especially 
IgAl subclass as described, this unique property led us to adopt it as an 
efficient yet economic affinity adsorbent to isolate human serum IgA for 
laboratory study. In addition to IgA, several serum proteins had also 
been found to bind jacalin, hence JBP was further separated by gel 
filtration with Fast Protein Liquid Chromatography (FPLC). By using 
this technique, we realized that JBP was heterogeneous. Therefore, it 
was necessary to isolate or purify the IgA-containing protein fractions 
from other impurities. In the course of our study, a protein fraction was 
consistently found to co-elute with IgA and it was well separated from 
IgA by FPLC. The remarkable quantity and quality of this protein in the 
JBP prompted us to identify it as this experimental design had the 
potential to develop a novel method for purification of this unidentified 
protein. Preliminary characterization of this protein and screening of 
available publications suggested that this protein is not a commonly 
known JBP, hence, it may be of practical value to identify it. As the 
unknown JBP was finally identified as 0C2HSG, the binding of 0C2HSG to 
jacalin was also analyzed. 
2.2 Identification of The Unknown JBP 
2.2.1 Sera 
Ten millilitres of peripheral blood was obtained by venipuncture 
from each of 30 healthy human volunteers. The clotted blood was 
centrifuged at 3000 rpm for 10 minutes and the sera were aliquoted and 
stored at -20°C until use. 
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2.2.2 Isolation of JBP by Affinity Chromatography 
JBP was isolated by affinity chromatography using Econo System 
(Bio-RAD, Hercules, California, USA). Briefly, 4 ml serum was 
centrifuged at 16000 rpm for 5 minutes and diluted in 1:1 with jacalin 
column equilibrating buffer (JEB) containing 20 mM sodium phosphate, 
150 mM sodium chloride, 0.02% sodium azide, pH 7.4 The diluted sera 
were loaded to 5 ml Jacalin-agarose column (Pierce Chemical Co, 
Rockford, 111., USA). After washing with JEB until the optical density 
(O.D.) of the effluent at 280 nm was below 0.01，JBP were eluted with 
elution buffer containing 0.1 M melibiose (Sigma Chemical Co., St. 
Louis, Missouri, USA) in JEB. The JBP was then concentrated and were 
dialysed against PBS to 200 i^L The isolated JBP was aliquoted and 
stored at -20°C until use. 
2.2.3 Fast protein liquid chromatography (FPLC) of JBP 
Gel filtration chromatography of JBP was performed at room 
temperature by FPLC system (Pharmacia, Uppsala, Sweden). The 
. system possessed a LCC-500 controller, a high precision pump (P-500), 
a monitor (Dual Path Monitor UV-2 with both control and optical units), 
a fraction collector (FRAC-100), and a recorder (REC-481). The parame-
ters for programming of the FPLC system are shown in appendix in. In 
order to achieve better separation, two Superose columns (Superose 12 
prep grade and superose 6 prep grade, 10 x 300 mm, Pharmacia, Uppsala, 
Sweden) were connected and the column was calibrated with the high 
molecular weight Gel Filtration Calibration Kit (Pharmacia) which 
22 
% 
included bovine serum albumin (BSA) (67,000), aldolase (158,000)， 
ferritin (440,000), thyroglobulin (669,000), and blue dextran (2000,000). 
Two hundred gl of JBP were loaded onto the column and gel filtration 
was carried out at a flowrate of 0.2 ml per minute using PBS containing 
0.02% sodium azide, pH 7.4 as elution buffer. Fractions of 0.5 ml were 
collected and stored at -20eC for further analysis. 
2.2.4 Affinity chromatography with anti-human IgA column 
FPLC fractions containing IgA and IgA-associated complexes 
were identified by passing the affinity-purified JBP through an anti-
human IgA affinity column and the unbound- and bound-JBP fractions 
were subjected to FPLC, respectively. The profiles were compared with 
the profile of an untreated-control JBP. Anti-human IgA affinity column 
was prepared by coupling monoclonal rabbit anti-human IgA antiserum 
(Dakopatts, Copenhagen, Denmark) to CNBr- activated Sepharose-4B 
(Pharmacia) in accordance to manufacturer's recommendation. Briefly, 
one gram of freeze dried powder was suspended in 1 mM HC1 and was 
washed with 200 ml 1 mM HC1 on a sintered glass filter. The gel was 
equilibrated with about 100 ml coupling buffer containing 0.1 M 
NaHC03, 0.5 M NaCl, pH 8.3. About 0.8 mg antiserum was diluted in 3 
ml coupling buffer and mixed with 2 ml gel in a stoppered vessel. The 
mixture was rotated end-over-end for 3 hours at room temperature. After 
coupling, the excess ligand was washed away with coupling buffer and 
any remaining active groups were blocked with 1 M ethanolamine, pH 9， 
for 2 hours at room temperature. Finally, the coupled-gel was washed 
with three cycles of alternating pH: each consisting of a wash with 
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0.1 M acetate buffer, pH 4，containing 0.5 M sodium chloride followed 
by a wash with 0.1 M Tris buffer, pH 8，containing 0.5 M sodium 
chloride. The prepared anti-human IgA affinity column was connected 
to Econo system for isolation of the IgA and IgA-containing proteins in 
JBP. Briefly, 1.5 mg of JBP diluted in 3 ml PBS was loaded onto the 
anti-human IgA affinity column. The unbound fraction containing the 
IgA-depleted JBP was collected for FPLC analysis. The column was 
then washed with PBS until the effluent O.D. at 280 nm fell below 0.01. 
The elution buffer contained 0.1 M glycine-HCl at pH 2.5 and the eluted-
protein was dialysed against PBS and concentrated for FPLC analysis. 
2.2.5 Preparation of non-IgA JBP fraction 
After separating the non-IgA JBP fraction in FPLC profile with 
anti-human IgA affinity column, the non-IgA. JBP fractions with MW of 
35-80 kDa from FPLC runs were pooled and then further purified by 
passing the fractions through the anti-human IgA affinity column to 
remove the contamination by IgA. The unbound fraction of anti-human 
IgA column was then dialysed against PBS and stored at -20°C in 
aliquots. This purified non-IgA JBP was used for further analysis by N-
terminal sequencing, ELISA and immunochemical characterization. 
2.2.6 N-terminal sequencing of the non-IgA JBP fraction 
N-terminal sequencing was performed to further identify the non-
IgA JBP. Preparation of protein for sequence analysis was modified 
from the method described by Chang et. al (51). Briefly, non-IgA JBP 
were first separated by SDS-PAGE on a 10% discontinuous 
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polyacrylamide gel. After separation, the protein bands were electro-
blotted onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad). 
Before blotting, the membrane was wetted in 100% methanol for 1 
minute, and then equilibrated in blotting buffer for 5 minutes. Electro-
blotting was carried out in a minigel tank (Bio-Rad) at 4°C for one hour 
at 5 mA/cm2 in 1.5% acetic acid and 20% methanol. After blotting, the 
membrane was rinsed with four changes of double distilled water and 
was stained with 0.025% Coomassie Brilliant Blue in 45% methanol and 
10% acetic acid for 5 minutes. The membrane was then destained for 15 
minutes followed by washing extensively with double distilled water to 
neutral pH. Finally, the membrane was dried by blowing with a stream 
of cool air and stored under -20°C until sequence. Automated cycles of 
Edman degradation were performed with an Applied Biosystems 
gas/liquid Model 470A/900A sequencer with an on-line Model 120 A 
phenylthiohydration (PTH)-amino acid analyzer (51). The N-terminal 
sequence was used to search for the matched-protein by using the 
Wisconsin Package (Genetics Computer Group, Version 7.3, June 1993， 
Madison, Wisconsin, USA 53711). 
2.2.7 SDS-PAGE and immunoblot of gel filtration fractions 
Fractions collected from gel filtration were separated by electropho-
resis on 10% polyacrylamide gel under either reducing or non-reducing 
condition. For immunoblot, the electrophoretic-separated proteins were 
electroblotted onto Zetaprobe (Bio-Rad). Briefly, blotting was per-
formed in blotting buffer containing 20 mM Tris, 192 mM glycine, pH 
8.3, at 100 V for one hour under 4°C. The blotted membrane was then 
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blocked with 10% BSA (Fluka BioChemica, Buchs, Switzerland) in 
PBS-azide overnight at 25°C and washed thrice with PBS containing 
0.05% tween-20 (PBS-tween) for 10 minutes. The washed membrane 
was incubated with appropriately diluted primary antisera for two hour at 
25°C and again washed five times for 10 minutes. The membrane was 
then incubated with horseradish peroxidase conjugated secondary 
antiserum for one hour at 25 °C. Finally, the membrane was developed in 
freshly prepared substrate containing 2.2 mM 4-chloro-1 -naphthol 
(Sigma) and 0.03% hydrogen peroxide at pH 7.4. 
2.2.8 ELISA of FPLC fractions of JBP 
FPLC fractions of JBP were analyzed by ELISA to examine the 
distribution of IgA and 0C2HSG. Briefly, 96 wells Immulon 2 microliter 
plates (Dynatech，Marnes la Coquette, France) were coated with 100 [il 
of goat anti-human 0C2HSG (Accurate Chemical and Scientific, 
Westbury, NY, USA) or rabbit anti-human IgA (Dako, Kyoto, Japan) in 
the dilution of 1:1000 or 1:10000 with 0.1 M carbonate-bicarbonate 
buffer, pH 9.6. The plates were incubated overnight at 4°C and were 
then washed thrice with PBS containing 0.05% tween-20 (PBS-tween), 
pH 7.4. After blocking the nonspecific sites with 1% BSA in PBS, the 
plates were again washed three times with PBS-tween. One hundred 
of diluted gel filtration fractions of JBP were introduced. After incuba-
tion at 37°C for three hours, the plates were washed thrice with PBS-
tween and 100 |Lil of rabbit anti-human IgA with horseradish peroxidase 
(HRP) conjugate (Dako) or biotinylated jacalin (Pierce) in the dilution of 
1:10000 and 1:1000 were added. For a2HSG ELISA, the plates were 
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washed three times with PBS-tween. One hundred |il of streptavidin 
with HRP conjugate (Tago, BurUname, California, USA) in the dilution 
of 1:5000 were added and incubated for a further one hour at 37°C. After 
incubation, the plates were washed four times with PBS-tween and 100 
|il freshly prepared substrate solution containing 0.034% (w/v) O-
phenylenediamine powder (Sigma) in 10 ml citrate/phosphate buffer with 
urea hydrogen peroxide (Sigma) were added. The plates were incubated 
at room temperature for a further 10 minutes and the reaction was 
stopped with 100 jil 2 M sulfuric acid. Finally, the reaction was 
terminated by addition of 50 ^il per well 1 M sulfuric acid, and the 
absorbances were measured at 490 nm using a Dynatech Microplate 
Reader (Dynatech). 
2.2.9 Immunochemical analysis 
Reactivity of JBP fractions to rabbit anti-human IgA, anti-human 
(X2HSG, and anti-human whole serum (Organon Teknika-Cappel, 
Turnhout, Belgium) was determined by immunoelectrophoresis. 
Furthermore, JBP fractions from FPLC were also analyzed with agarose 
gel electrophoresis by using the Paragon Serum Protein Electrophoresis 
(SPE) Kit (Beckman, Faraday St., California, USA). Precipitation 
reaction of the different antisera against JBP fractions was studied by 
standard immunodouble diffusion using 1.5% agarose gel. The follow-
ing antisera had been tested: rabbit anti-human C6 (Serotec, Kidlington, 
Oxford, UK)，rabbit anti-human C7 (Serotec), sheep anti-human albumin 
with horseradish peroxidase conjugate (Serotec), goat anti-human CI 
inhibitor (Sigma), anti-human ceruloplasmin (Beckman), anti-human 
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haptoglobulin (Beckman), and anti-human a 1-antitrypsin (Beckman). 
The JBP isolated using jacalin-agarose from Sigma was compared with 
that from Pierce for their immunoreactivity against anti-human o^HSG 
by using immunodouble diffusion. 
2.3 0C2HSG: the property of jacalin binding 
2.3.1 0C2HSG -jacalin binding curve and competitive ELISA 
For dose-dependent and competition ELISA of jacalin-a2HSG 
binding, non-IgA JBP (section 2.2.5) was used in the dilution of 1:1000. 
The procedures of both ELISA were the same as described (section 
2.2.8) except non-IgA JBP (purified 0C2HSG) was applied in various 
concentrations for the former assay; whereas in the latter assay, D-
galactose, a-lactose, D(+) mannose, B-D(-) fructose, melibiose, a-D(+)-
fucose or a-D(+)-glucose solution prepared as a stock of 100 mM in PBS 
was applied 50 \i\ per well in five-fold dilution together with 50 |Lil 
biotinylated-jacaUn in the dilution of 1:500 with PBS. For the competi-
tive effect of human IgG, human albumin and human IgA on the binding 
of jacalin to 0C2HSG. The human IgG was affinity-purified with Protein-
G agarose and IgA contaminant was removed with rabbit anti-human IgA 
sepharose-4B column, the purity of IgG was further analysed with SDS-
PAGE. Highly purified human albumin was prepared from a crude 
preparation of human albumin (Plasbumin-25, Miles Inc., Kankakee, 111” 
USA) with FPLC and the fractions of molecular weight corresponding to 
human albumin (66 kDa) were pooled for later use. Human IgA was 
purified by FPLC of anti-human IgA affinity column eluate. The three 
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jacalin (20 |Hg/ml). 
2.3.2 Purification of jacalin-crude extract (JCE) 
As the commercially available jacalin-agarose has so many 
unknown factors that could introduce difficulties for the present study, 
therefore, "home-made" jacalin was prepared and was used to compare 
with the commercially available jacalin. Jackfruit imported from 
Singapore was purchased from the local market, and over 150 seeds of 
weight 1.5 kg were obtained from a single jackfruit. Jacalin crude extract 
(JCE) was prepared as described (33). Briefly, jackfruit seeds were first 
washed and air dried, then the skin was removed and further rinsed with 
distilled water. The washed and skined seeds were minced with a 
blander in cold PBS. The suspension was allowed to stand overnight 
under 4°C with agitation. 
2.3.3 Characterization of JCE and ASJ 
To analyze the protein components of JCE and ASJ, concentrated 
protein fraction was subjected to FPLC in Superose columns as described 
(section 2.1.3). The peak fractions were pooled (JCE1 and JCE2) and 
concentrated for competitive ELISA study. Different jacalin prepara-
tions were also analyzed by SDS-PAGE in 10% polyacrylamide gel 
under reducing or non-reducing condition (section 2.1.7). The immuno-
logic reactivity of these jacalin preparations with IgA were examined by 
immuno-double diffusion in 2% agarose (section 2.1.9). 
2.3.4 Comparison of jacalin from different sources for binding to 0C2HSG 
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2.3.4 Comparison of jacalin from different sources to bind 0C2HSG by 
competitive ELISA 
Binding of jacalin (from different sources) to 0C2HSG was studied 
by competitive ELISA as described (section 2.3.1). In the present study, 
commercially available jacalin including that from Pierce and Sigma, and 
the "homemade" jacalin (ASJ) were examined for their ability to inhibit 
the binding of biotinylated-jacalin to a2HSG. All jacalin samples were 
prepared in a stock of 1 mg/ml. Working jacalin solution was prepared 
by two-fold serial dilution of the stock jacalin solution with PBS in a 
separate microtiter plate and equal volume of biotinylated-jacalin (20 
|Xg/ml) was introduced, 100 i^l of the mixed jacalin working solution 





3.1 Identification of the unknown JBP 
3.1.1 Isolation and FPLC of JBP 
Fig.1.1 shows a typical FPLC profile of JBP with two major peaks 
of molecular weight (MW) corresponding to 440 kDa (P2) and 67 kDa 
(P3) together with one minor peak of MW corresponding to 667 kDa 
(PI). When the amount of peak protein was expressed in terms of 
percentage of total JBP, PI, P2，and P3 represented 8.8±0.5%, 
65.6±1.0%, and 24.0±0.9% for 30 normal sera, respectively. The protein 
concentration of P3 was equivalent to 0.4±0.1 mg per ml serum. Four 
different batches of jacalin-agarose column were used and similar FPLC 
profiles were obtained. 
3.1.2 Identification of non-IgA JBP by anti-human IgA affinity column 
Fig. 1.2a and 1.2b showed the FPLC chromatograms of JBP before 
and after passing through the anti-human IgA affinity column. After 
affinity chromatography, PI and P2 were removed yet P3 was not 
affected. This indicated that P3 did not react with anti-human IgA and 
should not be IgA or IgA containing proteins. This was further con-
firmed by eluting the anti-human IgA bounded proteins and 
rechromatographed by FPLC. The chromatogram was illustrated in 
Fig. 1.2c，which showed that no protein could be detected in the fractions 
corresponding to P3. To further locate the IgA and IgA containing 
protein in the JBP FPLC profile, individual fractions of the gel filtration 
were analyzed by anti-IgA sandwich ELISA. The distribution of IgA 
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Fig.1.1 The typical FPLC profile of JBP. Peak 1 (PI), peak 2 
(P2)，and peak 3 (P3) are three peaks of FPLC. Column: 
Superose 6 and Superose 12, (10x300mm) x 2. Eluent: 
PBS, 0.01 M，0.05% sodium azide, pH 7.4. Flowrate: 0.2 
ml/min. Fraction size: 0.5 ml. Arrow: void volumn. 
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Fig. 1.2 Anti-human IgA affinity chromatography and ELISA 
of IgA in the FPLC fractions, (a) FPLC profile of JBP. 
(b) FPLC profile of the unbound fraction of anti-human 
IgA affinity column, (c) FPLC profile of anti-human IgA 
affinity column eluate. (d) ELISA profile of IgA in the 
FPLC fractions. FPLC conditions: Column, Superose 6 
and Superose 12, (10x300mm) x 2. Eluent: PBS, 0.01 M, 
0.05% sodium azide, pH 7.4. Flowrate: 0.2 ml/min. 
Fraction size: 0.5 ml. 
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3.1.3 Identification of the known JBP in the FPLC fractionated JBP 
ELISA (Fig. 1.3) of the FPLC fractionated JBP showed that CI-
INH was mainly distributed in the trail region (fraction 45-50) of P2. 
SDS-PAGE and Western blotting of the pooled peak fractions also 
displayed the exclusive distribution of Cl-INH in P2 (Fig. 1.4). By using 
immunodouble diffusion, human serum albumin (HSA) was not detected 
in the FPLC fractionated JBP. . 
3.1.4 Characterization and confirmation of non-IgA JBP 
SDS-PAGE of non-IgA JBP revealed the existence of a 55 kDa 
protein (Fig. 1.5). By agarose gel electrophoresis, we demonstrated that 
this 55 kDa protein had an electric-mobility in the ( X 2 - g l o b u l i n region 
(Fig. 1.6a). As the non-IgA JBP were not found to be one of the known 
JBP including human serum albumin and CI-inhibitor, hence, N-terminal 
sequencing of this 55 kDa protein was performed and a fragment of 
sequence A P L P P G L I Y R Q S N was identified. Upon searching 
with the on-line protein bank, 0C2HSG was found to be the only known 
human serum protein that contains such a sequence. As 0C2HSG is a 50-
55 kDa serum protein of (^-mobility (36)，and it possesses several O-
linked oligosaccharide moeities that are similar to T-antigen (39, 41), we 
suspected that 0C2HSG is the likely candidate of P3. 
To confirm this hypothesis, the identity of FPLC purified P3 was 
analyzed by immunochemical techniques. By immunoelectrophoresis, 
P3 formed a precipitation arc against rabbit anti-human 0C2HSG but not 
36 
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Fig. 1.6 Immunochemical analysis of non-IgA JBP (P3). 
(a) Agarose gel (2%) electrophoresis. Arrow: position of 
sample loading. N1 and N2: normal sera. 1-3: non-IgA JBP 
from three different preparations, (b) Immunoelectrophoresis. 
1: normal human serum. 2 and 5: P3 JBP. 3: standard human 
a2HSG (Calbiochem). 4: JBP. A and C: goat anti-human whole 
serum. B: goat anti-human a2HSG. D: rabbit anti-human IgA. 
(c) 1: void volumn. 2-4: P1-P3 of FPLC fractionated JBP. S: 
normal serum. G: goat anti-human a2HSG. 
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with anti-human IgA. The position of precipition arc was in a-region. 
These observations were in good agreement with that of the human 
agHSG standard (Fig. 1.6b). Immunodouble diffusion also showed that 
no immunologic reactivity between P3 and specific anti-human antisera 
against C6, C7, CI-inhibitor, ceruloplasmin, haptoglobulin, albumin and 
a 1-antitrypsin (data not shown). By Western blotting, anti-human 
(X2HSG was shown to react only with the 55 kDa band as well as a 
standard 0C2HSG (Calbiochem, San Diego, USA) (Fig. 1.5). With 
Jacalin-a2HSG ELISA (section 2.3.1), CX2HSG was located in fractions 
50 to 58 (P3) but not PI and P2 (Fig. 1.7). 
3.2 0C2HSG: the property of jacalin binding 
3.2.1 Characterization of azHSG-jacalin binding 
After confirming that P3 is azHSG，0C2HSG enriched non-IgA 
JBP was obtained by pooling P3 fractions from different experiments. 
These fractions were used for further analysis of a2HSG-jacalin binding. 
Using ELISA, a dose-dependent interaction between 0C2HSG and Jacalin 
was demonstrated (Fig丄8). The detecting limit of this ELISA system in 
measuring 0C2HBG was 1 ng/ml. When the binding was farther character-
ized by competitive ELISA, human serum IgA and human colostrum 
slgA exhibited strong inhibitory effect on the binding of azHSG to 
jacalin whereas human IgG and human albumin failed to do so 
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Fig.1.7 ELISA profile of 0C2HSG in the FPLC fractionated 
JBP. Dotted Une: FPLC profile of JBP. Solid line: ELISA 
profile of (X2HSG. 
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Fig. 1.8 Dose-dependent binding of biotinylated-jacalin to various 
concentrations of odHSG. (a) The saturated curve of 
biotinylated-jacalin to bind various concentrations of azHSG. 
(b) The linear region of (a). 
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(Fig. 1.9a). Furthermore, the binding of (X2HSG to jacalin was strongly 
inhibited by low concentration of D-galactose and melibiose. Maltose 
and fucose showed weak inhibition whilst lactose, mannose, glucose, 
fructose, and maltose did not affect 0C2HSG binding to jacalin (Fig. 1.9b). 
3.2.2 Characterization of the purified jacalin 
FPLC fractionation of JCE and ASJ are shown in (Fig. 1.10a). The 
JCE contains three minor proteins (67，43，and 34 kDa) and a major 
component (24 kDa). As the three minor components did not bind to 
IgA-Sepharose 4B affinity column, these fractions were pooled (JCE1) 
for further analysis. Upon IgA-Sepharose purification, the ASJ contains 
only a 24 kDa component (Fig. 1.10a). SDS-PAGE of the ASJ (Fig.1.11) 
displays two prominent bands corresponding to 12 and 15 kDa under 
either reducing or non-reducing conditions, and these two components 
were also found in the purified jacalin from Pierce. SDS-PAGE of JCE 
(Fig. 1.10a) displays three prominent components (24，28, and 40 kDa) 
and, the 24 kDa component was broken down and some of the 
degradative products has the MW of about 16 kDa. Immunodouble 
diffusion of both JCE and ASJ against human IgA had shown strong 
precipitin formation (Fig. 1.1 Ob). 
3.2.3 Comparison of different batches of jacalin to interact with 0C2HSG 
Competition ELISA was performed to determine whether jacalin 
from different preparations [including commercially available products 
(Pierce and Sigma) as well as the home-made jacalin] showed different 
binding capacity with (X2HSG. The result demonstrated that jacalin from 
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Fig.1.9 Competitive ELISA. (a) Binding curves of jacalin-biotin 
to oczHSG with increasing concentration of human IgG (s), 
human serum albumin (©), human colostrum slgA (•)，and 
human serum IgA (•). (b) Binding curves of jacalin-biotin 
to 0C2HSG with increasing concentration of D-galactose 
(0)，a-lactose (口)，D(+) mannose (o), p-D(-) fructose (x), 
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Fig.1.10 Characterization of JCE and ASJ. (a) Chromatogram of 
the FPLC fractionated JCE and ASJ. Dotted line: ASJ 
profile. Solid line: JCE profile. FPLC conditions: Column, 
Superose 6 and Superose 12 (10x300mm) x 2; eluent, PBS, 
0.01 M, 0.05% sodium azide, pH 7.4; flowrate, 0.2 ml/min. 
(b) Immunodouble diffusion of different jacalin 
preparations. 1: JCE. 2: JCE1. 3: JCE2. 4: blank. 5: 
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Fig. 1.11 SDS-PAGE analysis of jacalin in 10 % Polyacrylamide 
gel. 1: ASJ. 2: purified jacalin from Pierce. 3: JCE. M: 
marker. 
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all preparations competed with the biotinylated-jacaUn to bind a2HSG in 
a dose-dependent manner (Fig. 1.12) and all the inhibitory curves 
exhibited similar trends. Hence, we conclude that the binding of jacalin 
to a2HSG is a natural property although it varies slightly with jacalin 


























































































































































































































In the experiment during which we purified human IgA using 
jacalin-agarose column, we consistently observed a 55 kDa serum protein 
of'alpha electro-mobility that was co-eluted with IgA. Previous studies 
have reported that jacalin could bind some unknown serum protein of 
alpha electro-mobility (7). To the best of our knowledge, this 55 kDa 
protein does not belong to known JBP. By N-terminal sequencing, the 55 
kDa was identified as alpha-2 HS glycoprotein (a^HSG). We further 
showed that the binding of jacalin to o^HSG occurred in jacalin from 
different geographic areas (Malaysia, India) and with different prepara-
tions (commercial or self-prepared). 
Protein sequence of human ocgHSG has 68% homology with that 
of bovine fetuin (52, 53，144)，and the latter was found to bind jacalin 
due to the presence of the O-linked trisaccharides (54). Jacalin is known 
to have specific affinity for the O-linked disaccharides 
(Gal(31 ->3GalNaca 1 ->0) that is found in the hinge region of the heavy 
chain of IgA molecules (21，55). The O-linked trisaccharides of bovine 
fetuin are sialated (NeuAca2^3Galpl ->3 GalNac al-^0) and apparent-
ly, this does not prevent binding with jacalin but appears to decrease the 
binding affinity (54). The same O-linked trisaccharides are also found in 
both A-chain (Thr 238，252) (41) and B-chain (Ser 6) (39) of a2HSG. In 
the present report, we demonstrated the dose-dependent binding of 
jacalin to increasing concentration of o^HSG and we also showed that 
IgA competed with 0C2HSG to bind jacalin, Furthermore, galactose and 
melibiose exhibited the strongest inhibition on the oczHSG-jacalin 
binding. According to these findings, we suggested that the reactive loci 
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of (X2HSG to jacalin are the O-linked trisaceharides. 
The competition of a2HSG and IgA for the jacalin-binding site 
may cause some potential interferences when jacalin is used in certain 
experiments. Firstly, when using immobilized-jacalin to quantify IgA 
and its associated immune complexes (55), competition of other JBP 
(such as 0C2HSG) for the same jacalin-binding site may lead to 
underestimation of the true value. Furthermore, as the serum level of 
these competitors varies from one individual to another, error would be 
expected when the assay is used for comparing the different samples. 
Secondly, when jacalin is used as a probe to localize special antigens, 
such as IgA immune complexes (61) or Thomsen-Friedenreich antigen 
on the cell surfaces (22), the investigator must be certain that other JBP 
are not present on the cells. Thirdly, when jacalin is used to purify 
serum IgAl for cell function studies (such as phagocytosis), the interfer-
ence of the target cells by these non-IgA JBP should also be considered 
to prevent false positive result. Actually, 0C2HSG has been known to 
behave as an opsonin (45) and has been demonstrated to enhance the 
phagocytosis of human monocyte in a dose-dependent manner (46). 
Hence, it may compete with IgAl for opsonisation and may magnify the 
effects on the subsequent phagocytic functions if its concentration is 
high. 
By using competitive ELISA, jacalin preparations from different 
geographical regions or manufacturers were shown to bind 0C2HSG with 
slight variation. This proves that the property of (X2HSG-jacalin interac-
tion is genuine. The ASJ was shown to contain a homogeneous 24 kDa 
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component that is smaller than any reported MW of intact jacalin [36-66 
kDa (7-11) ]• The most likely interpretation is that jacalin was broken 
down to subunits during the purification process. SDS-PAGE (10% 
polyacrylamide) revealed that ASJ was consisted of two components of 
12 and 15 kDa (6，9，12). They are referred to as a-chain (12 kDa) and 
a'-chain (15 kDa) as shown previously (16). According to Kabir et al. 
(9)，both subunits bind human IgA. However, we did not detect intact 
jacalin (40 kDa) in the ASJ under either the reducing or non-reducing 
conditions as reported previously (9). 
In conclusion, we have identified that human serum 0C2HSG is a 
JBP, and we have developed a novel method to purify 0C2HSG and to 
measure serum 0C2HSG. The binding properties of 0C2HSG with jacalin 
were studied and we propose that the binding mechanism of jacalin to 
0C2HSG is similar to that of bovine fetuin to jacalin. This property of 
jacalin may pose potential interference when it is adopted for rapid IgA 
purification and solid-phase detection of IgAl in some experiments. 
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Part II 





The precise physiological function of (X2HSG is mostly unknown 
and it belongs to the group of plasma proteins in search of a function 
(56). Hence, highly purified and functional 0C2HSG is needed for 
elucidation of its physiologic role. Table 2.1 summarizes the available 
conventional methods for purification of CX2HSG. The obvious disadvan-
tage is that these methods are time-consuming and very complicated. 
Conventional methods for accurate quantitation of serum 0C2HSG 
level relies solely on single radial immunodiffusion (37，46，48，56，57) 
or rocket immuno-electrophoresis (43) with reference to a serial diluted 
standard serum of known 0C2HSG concentrations. However, both 
methods require a large amount of antiserum that is extremely expensive. 
In the previous section, the observation that jacalin can interact with 
human serum (X2HSG was described. This finding has led us to develop 
a simple and convenient method for quick purification of 0C2HSG. The 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Materials and Methods 
61 
6.1 Preparation of IgA-specific jacalin (ASJ) by IgA-Sepharose 4B 
affinity column 
Purification of IgA-specific jacalin was achieved by affinity 
chromatography in a IgA-Sepharose 4B column as described previously 
(11，21). Briefly, human IgA was obtained by pooling fractions of PI 
and leading-edge of P2 from several FPLC runs of JBP. In fact, pooling 
the fractions in this manner could minimize the contamination of IgA 
pool by the non-IgA JBP, namely P3. Affinity chromatography was 
performed by connecting the IgA-Sepharose 4B column to the Econo 
System. To obtain ASJ, JCE was passed through the IgA-Sepharose 4B 
column and the unbound JCE fraction was washed with PBS until the 
O.D. at 280 nm was below 0.01. The bound-protein was eluted by adding 
JEB, the eluted ASJ was concentrated with Amicon and was dialysed 
with PBS. 
6.2 Preparation of JCE- and ASJ-Sepharose-4B affinity column 
The protocol for preparation of these two columns is the same as 
described in anti-human IgA-Sepharose 4B preparation (2.1.4) except the 
ligands used for coupling was JCE or ASJ. The ligands used in preparing 
JCE- and ASJ-Sepharose 4B were concentrated JCE and ASJ, respective-
ly. The performance of these affinity columns was evaluated by connect-
ing them to Econo System for isolation of JBP from human serum. 
Accordingly, both columns could extract—over 95% JBP from 1 ml serum 
per 3 ml gel in a single extraction process. 
6.3 Factors affecting the yield of 0C2HSG 
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^ of «2HSG was analyzed. To analyze the effect of serum dilution, 
immobilized-jacalin columns included (1) commercially available 
jacalin-agarose from Pierce Chemical Co. and Sigma Chemical Co., and 
(2) self-prepared ASJ-Sepharose 4B and JCE-Sepharose 4B were used. 
The pooled serum from normal controls was applied to each column in 
the dilution of 1:1 with JEB and the unbound protein was washed with 
JEB until the O.D.280 nm of effluent was fell below 0.01. The JBP was 
eluted by adding 0.1 M melibiose in JEB. The same practice was also 
applied to the serum samples in the dilution of 1:5 and 1:15. To compare 
the yield of 0C2HSG，the JBP eluted from each column was subjected to 
FPLC and the peak height ratio of P2 and P3 was used as a measure of 
efficiency to isolate 0C2HSG. 
To clarify whether serum albumin will affect the yield of 0C2HSG， 
a Hi-Trap Blue-sepharose (HTB) column (5 ml) (Pharmacia) was used to 
remove the serum albumin (56). By using ELISA, the unbound fraction 
of HTB column contains less than 5% serum albumin. The albumin-
reduced serum was divided into two fractions and each was applied to 
jacalin-agarose (Pierce) or ASJ-sepharose-4B for JBP isolation. Control 
samples in which albumin was not removed were run in parallel in 
jacalin-agarose (Pierce) or ASJ-sepharose 4B columns. 
6.4 Miscellaneous methods 
SDS-PAGE was carried out as described (section 2.2.7). Specific-
ity test of the jacalin-a2HSG ELISA was carried out as described in 
section 2.3.1 except that a standard (X2HSG (Calbiochem，San Diego, 
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USA) was used instead of non-IgA JBP fraction (section 2.2.5). Yield of 
oc2HSG from either serum (6 ml) or plasma (5 ml) was measured by 




Results and Discussion 
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In the previous section we have shown that a2HSG is a JBP and this 
section describes a novel method for quick purification of a2HSG. This 
method includes only two steps: jacalin-agarose affinity chromatography 
and FPLC fractionation of JBP with Superose column. The first step is 
critical as the binding of a2HSG or IgA to jacalin is similar, and the 
serum concentration of IgA (2-3 mg/ml) is higher than a2HSG (0.6 
mg/ml). Hence, a potential inhibitory effect of serum IgA on the binding 
of 0C2HSG to jacalin occurs unless IgA is largely removed. That involves 
a complicated purification. In the present experiment, a higher serum 
dilution is shown to improve the yield of 0C2HSG. The use of jacalin-
agarose chromatography is an advantage for purification of 0C2HSG 
because jacalin reacts only to a small number of serum proteins (24，31, 
60). The second step utilizes the gel filtration to separate these different 
JBP from each other. This step is so efficient as IgA and Cl-INH are 
well separated from 0C2HSG. 
Isolation of 0C2HSG by using immobilized-jacalin from different 
sources showed that IgA constituted the predominant protein of JBP, 
while only the jacalin-agarose from Pierce yielded remarkable quantity 
of (X2HSG when compared with the others. Table 2.2 shows the yield of 
0C2HSG from either serum or plasma when jacalin-agarose Pierce was 
used. It is due to the relatively low yield of 0C2HSG from other jacalin 
columns (Sigma and "home-made"), the effect of serum dilution and 
serum albumin on the recovery of 0C2HSG was analyzed. The yield of 






































































































































































































































































































































































































































































































































































• 1 :5 > 1:1) f o r a11 columns (Fig.2.1) and removal of serum albumin did 
not improve the yield of a2HSG (Table 2.3). 
The advantages of this method over the conventional methods 
include: (1) a shorter time for purification: less than 5 hours as compared 
to over 50 hours with other methods (35，36，42，58，59)，(2) the method 
is simple to perform, (3) all purification steps can be done under room 
temperature with no adverse effect on the immunologic reactivity of 
oc2HSG as confirmed by immunoelectrophoresis, immunodiffusion and 
western blotting, (4) provides better buffering capacity for the a2HSG as 
the whole process is performed under physiologic pH (7.4): the purified 
(X2HSG is functionally active and the immunoreactivity can be retained 
after storage at -70°C for more than six month (Fig.2.2), (5) because low 
cost jacalin is an inexpensive and stable lectin, it would be an ideal 
adsorbent for affinity purification of (X2HSG，and (6) this method is very 
efficient for purification of 0C2HSG as over 95% 0C2HSG from either 
serum or plasma was bound to jacalin-agarose (Pierce) (Table 2.2), this 
also indicates that the present method is suitable for isolation or removal 
of total 0C2HSG from either serum or plasma. 
Pervious report had shown that HSA exhibited inhibitory effect on 
the recovery of IgAl from jacalin-agarose (30). We failed to demon-
strated that HSA was responsible for the low yield of 0C2HSG from 
immobilized-jacalin column. Furthermore, elimination of the HSA by 
Hi-Trap Blue Sepharose did not improve the yield of 0C2HSG. 
Beside using jacalin for purifying 0C2HSG，we also demonstrated a 
novel ELISA system to detect human o^HSG using anti-human 0C2HSG 
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Fig.2.1 Chromatograms of FPLC fractionated JBP from 
different jacalin affinity columns with different serum 
dilutions, (a) jacalin-agarose from Pierce, (b) jacalin-
agarose from Sigma, (c) JCE-Sepharose 4B. (d) ASJ-
Sepharose 4B. . Dotted line: 1:15 serum dilution. Solid 
line: 1:5 serum dilution. Thickened line: 1:1 serum 
dilution. Arrow indicates the fraction that 0C2HSG was 
eluted. 
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Fig. 2.2 Immunodouble diffusion of FPLC purified 
CC2HSG • 1: 0C2HSG enriched P3 fraction after store at 
4°C for one week. 2 and 3: PI and P2 fraction from FPLC 
fractionated JBP. S: normal serum. G: goat anti-human 
0C2HSG. The unlabelled wells contain the (X2HSG 
enriched P3 fraction after store at -70。C for over six 
months. 
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as the capturing antibody and biotinylated-jacalin as the detection 
reagent. We showed that the capturing antiserum, anti-human oc2HSG, 
reacted specifically with a2HSG but not with IgA or HSA (Fig.2.3a) 
despite the IgA and HSA were functionally active (Fig.2.3b). As IgA 
and HSA are major serum proteins, this interference should be awared 
when guantitative work is performed. This ELISA is specific for 
detecting the human 0C2HSG but not its serum counterpart (fetuin) from 
mouse, rabbit and bovine sera (Fig.2.4). 
There are several distinct advantages of this ELISA: (1) all reagents 
are commercially available, (2) the sensitivity of this ELISA (1 ng/ml) 
(Fig. 1.8) is much higher than the conventional rocket immunodiffusion 
techniques, hence, this assay system should prove a sensitive method for 
detection of low concentration of 0C2HSG, such as the (X2HSG level in， 
supernate of cultured hepatocyte, (3) the specificity of this ELISA is 
confirmed to be either species specific or antigen specific, and (4) this 
ELISA method allows handling of large number of samples simultaneous-
ly. Nevertheless, further investigation should be performed to evaluate 
the precision, reproducibility, and potential interference of this ELISA 
before it is used routinely as a human 0C2HSG assay. 
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Fig.2.3 Cross-reactivity test of a2HSG-jacalin ELISA. Table 2.4 
shows the list of antisera used in each test. First column in 
table 2.4 indicates the corresponding numerical legends 

































































































































































































































































































































































































































































































































































Fig. 2.4 Species specificity test of a2HSG-jacalin ELISA 
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An Overview of IgA Nephropathy 
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8.1 Clinical manifestation of IgA nephropathy 
IgA nephropathy (IgAN) was documented as a distinct form of 
nephritis by Jean Berger in 1968 when renal biopsies were studied with 
antiserum against human IgA. IgAN is the most common form of 
glomerulonephritis in many parts of the world (68，143). Clinically, 
microscopic haematuria, sometimes accompanied by mild proteinuria, is 
the most common clinical manifestation (69). Macroscopic haematuria, is 
frequently preceded shortly by upper respiratory tract infection or 
gastrointestinal infection (70). In the absence of effective treatment 
strategies, approximately 20% of patients progress to end-stage renal 
failure in 20 years, thus contributing a very heavy burden to dialysis and 
transplant programs (70). The recurrence of IgAN in renal allograft (71， 
72) and the clearance of the mesangial deposits in the renal allograft with 
IgAN by non-IgAN recipient, indicate the persistence of an extrarenal 
pathogenetic process. 
Histologically, IgAN is characterised by predominant deposits of 
IgA in the glomerular mesangium on immunofluorescence studies (73， 
74, 75，76). In at least one-third of cases, the immunofluorescent 
staining extends to adjacent capillary loops. The capillary deposition that 
often correlates with a more severe and diffuse mesangial proliferation, 
indicates a more severe lesion, with a poorer prognosis (77). Electron 
microscopy confirms the presence of electron-dense deposits in the 
mesangium. Light microscopic examination reveals a wide spectrum of 
abnormalities: the glomeruli may be normal or may show mesangial 
widening and segmental proliferation, diffuse mesangial proliferation, or 
rarely, overt crescentic glomerulonephritis (78). 
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The generally accepted diagnosis criteria for primary IgAN is to 
show the presence of mesangial IgA deposits in the absence of clinical or 
laboratory evidence of other systemic diseases including systemic lupus 
erythematosus (SLE), liver or biliary tract disease, and 
Henoch-Schoenlein purpura (HSP). 
8.2 Mesangial deposits in IgAN 
The presence of mesangial IgA deposits is required to fulfil the 
diagnostic criteria for IgAN. These deposits may extend to the 
paramesangial areas, and to the periphery of the capillary loops. The IgA 
deposits are predominantly IgAl, and sometimes with trace amount of 
IgA2. The codeposition of the IgG and/or IgM isotypes is reported with 
variable prevalence by different authors (79，80，81). In all reported 
studies, there is a high prevalence of C3 in the mesangial deposits, with a 
pattern very similar to that of IgA (75，76，81，82). Most investigators 
also find properdin (factor P), factor H and terminal sequence compo-
nents including C5, C6, C9, and the membrane attack complex in the 
deposits (82, 83). These findings suggest that the alternative complement 
pathway is involved and is carried through to the terminal phase. 
Although glomerular deposition of microbial antigens [cytomegalovirus 
(142)，hepatitis B core and surface antigens (84，85) ] and food antigens 
(86) were reported sporadically, the search for the antigen or antigens 
involved in the formation of the mesangial deposits awaits further 
studies. Furthermore, an excess of 入 light chain in the IgA mesangial 
deposits is found in a majority of IgAN (87, 88). 
The presence of polymeric IgA in the deposits is suggested by the 
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finding of J chain and their ability to bind secretory component (76, 89， 
90，91，92). However, there is still considerable disagreement on the 
relative importance of the polymeric IgA (86，92) as 
immunofluorescence studies fail to assess the relative contribution of 
polymeric IgA to the total IgA in the deposits. Moreover, the co-
deposited IgM, also a polymeric immunoglobulin, may well be respon-
sible for the J chain detected and for the binding of SC. Another 
approach to this question is by analyzing the eluted IgA from tissue 
specimens by gel filtration column chromatography (91，93, 94). Such 
studies also concluded that polymeric IgA constitutes a substantial 
fraction of the mesangial IgA. However, it is possible that the acid 
elution procedure, and the further manipulations involved, resulted in the 
formation of aggregates of IgA, leading to the overestimation of the true 
value of polymer content. 
In summary, there is uniform agreement that the mesangial IgA 
belongs to the subclass IgAl yet it is still a matter of debate what 
percentage of the mesangial IgA deposit is polymeric. 
8.3 Human IgA system 
The recurrence of IgAN in the renal graft and the findings of 
predominant IgAl in the mesangial deposits provide clues on the 
potential pathogenic role of the circulatory IgAl. A comprehensive 
summary of the structural, functional and cellular aspects of IgA has 
been review by Mestecky et al, (1987) (64). An unusual feature of 
human IgA is the heterogeneity of the molecular forms and its subclasses 
with characteristic distribution in mucosal and systemic IgA compart-
ments (64，95, 96). Although IgA undoubtedly plays an important role in 
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the defence against vast majority of microorganisms that constantly 
challenge our mucosal surfaces including respiratory tract, 
gastrointestinal tract, lacrimal glands, and urinary tract, approximately 
讀 one third of our IgA plasma cells serve another purpose. These cells are 
involved in the production of non-mucosal IgA, mainly plasma IgA. 
Adding up the mucosal and systemic productions, IgA is estimated at 65 
mg per kg body weight per day, which exceeds the total production of 
IgG (30 mg/kg/day) and IgM (8 mg/kg/day) (95，96). 
IgA exists in two subclasses: IgAl and IgA2, and the IgA2 has two 
allotypes including IgA2m(l) and IgA2m(2). The most remarkable 
structural differences between IgAl and IgA2 molecules are located in 
the hinge region of heavy chain: IgA2 has a deletion of 13 amino acid 
residues in this region (64)，and this deletion eliminates five serine 
^ residues with O-linked oligosaccharide moieties. As for the molecular 
form, IgA exists in three distinct molecular forms: 1. monomeric IgA 
(mlgA), composed of two heavy (a) and two light (K or X) chains. 2. 
dimeric or polymeric IgA (dlgA or plgA)，composed of two or more 
molecules of monomeric IgA, covalently linked within the IgA produc-
tion plasma cell through a 15 kDa polypeptide celled joining chain (J 
chain). 3. secretory IgA, consisting of dimeric or polymeric IgA 
covalently coupled to the SC. 
Although IgA is locally synthesized and secreted throughout the 
mucosal surfaces of the body, quantitatively, most important site of 
mucosal IgA production is the gastrointestinal tract because of its vast 
surface area with has an estimated daily output of IgA of 3400 to 7000 
mg in the adult (64). In comparison to this vast quantity, the production 
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by the respiratory tract (45 mg/day). lacrimal gland (1-6 mg/day)，and 
urinary tract (1-3 mg/day) is small (64). The IgA in the mucosal secre-
tion is largely polymeric (90%) (97). Seventy percentage of the IgA 
plasma cells in the lamina propria produce polymeric IgA, and the pig A 
is selectively transported through the cytoplasm of the overlying 
epithelial cells to the external milieu through the active SC mediated 
delivery system. Once the plgA is released from the luminal side of 
epithelial cell, part of the plgA receptor peptide remains attached to it to 
form the secretory component (SC), and the slgA is secreted. On the 
whole，the subclass IgAl and IgA2 contribute approximately 60% and 
40% respectively to the external secretions (97). In circulation, the bone 
marrow is the most important source of plasma IgA in human beings. 
The bone marrow produces predominantly monomeric IgAl, which 
constitutes 80-85% of the IgA subclass and 88-99.5% monomeric IgA 
distributed in the intravascular compartment. Smaller contributions to 
serum IgA are probably made by the spleen and peripheral lymph nodes, 
including the tonsils (95). 
Systemic and mucosal IgA are viewed as two separate systems of 
immune defense as the mucosal surfaces are neither the source nor the 
destination of systemic IgA. In many cases an immune response induced 
by a mucosal presentation of antigen remains limited to the mucosal area, 
and does not result in the appearance of specific antibodies in the plasma. 
This phenomenon has been termed ‘oral tolerance', which illustrates 
once more the view of separate intravascular and mucosal IgA systems. 
However, examples also exist where antigens encountered at mucosal 
surfaces may give rise to serum antibodies of the IgA class. This 
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illustrates that the compartmentalized IgA systems are actually interac-
tive to some extent. The lymphoid tissues primarily involved in the 
mucosal immune response are gut associated lymphoid tissue (GALT) 
and bronchus associated lymphoid tissue (BALT). For the former, 
specialized structure exists for the sampling of environmental antigens 
leading to the IgA response in the Peyer's patches. The lymphoreticular 
cell population in the Peyer's patches contains all the cell types necessary 
for the induction of immune response such as T and B cells, 
macrophages and dendritic cells. After an initial activation of IgA 
precursor B cells of the antigenicity concerned, these cells do not 
progress to the final stage of maturation, the IgA plasma cell, but first 
recirculate by way of the mesenteric lymph nodes, thoracic ducts and 
blood stream. From the blood stream they once more enter the mucosal 
tissue and then undergo their terminal differentiation to IgA secreting 
plasma cells. This repopulation of the mucosal tissues occurs in a 
widespread fashion and has led to the concept of the common mucosal 
immune system. Systemic presentation of antigens has been reported in 
numerous studies including: inactivated influenza virus, tetanus toxoid, 
rabbit anti-thymocyte immunoglobulin, and pneumococcal 
polysaccharides. One of the fascinating features of systemic presentation 
of antigen is that it also gives rise to IgA antibodies in mucosal secretion, 
especially in individuals who have previous encountered history of the 
antigen via the mucosal route. This observation illustrates once more 
that the IgA system can not be viewed as strictly compartmentalized. 
8.4 The role of circulating IgA in the pathogenesis of IgA nephropathy 
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Several observations suggest that the mesangial deposits in IgAN 
are derived from the circulation. Firstly, the mesangial deposits have the 
typical appearance, both by immunoflurescence and electron microscopy, 
of immune complexes. Secondly, some investigators have also found 
perivascular deposits of IgA at other sites in the body, including the skin 
and skeletal muscle, in patients with IgAN. Thirdly, IgA nephropathy 
recurs in renal grafts, while the deposits disappear when a graft contain-
ing mesangial IgA deposits is transplanted in a recipient not suffering 
from IgAN. Finally, predominant synthesis of IgA with X light chain in 
the serum of patients with IgAN and the predominant mesangial deposits 
of 入-IgA have been reported. These findings strongly indicate the 
correlation between serum IgA and the pathogenesis of IgAN. 
In addition, numerous investigators have found humoral and cellular 
abnormalities in the circulation of patients with IgAN. Firstly, the serum 
IgA level is elevated in most of the patients with primary IgAN. Second-
ly, many investigators have reported on the presence of what has been 
collectively termed 'macromolecular IgA，in the sera of patients with 
primary IgAN (98-101) • Thirdly, circulating immune complexes 
containing IgA have been detected in IgAN (102, 103) although no 
uniform conclusion of the size and subclass of the IgA is made. Fourth-
ly, despite the demonstration of immune complexes in IgAN, the 
antigens involved in the formation of the circulating immune complexes 
are largely unknown. Many suspected antigens include: food antigens 
(bovine serum albumin, gliadin, and alpha-lactalbumin) (100，104-106)， 
bacterial antigens (influenza, mycoplasma pneumonia, streptococcus, and 
pneumococcus) (104，107)，viral antigens (Epstein Barr virus, herpes 
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simplex virus, cytomegalovirus, and hepatitis B virus) (107，108). 
Endogenous antigens against which serum IgA antibody react have been 
reported includes C3 (or its breakdown products C3b，C3d，and iC3b)， 
fibronectin (109，110)，IgG (i.e. IgA rheumatoid factor) (111-114)，or 
even Fab fragment of IgA (i.e. IgA autoantibody) (115). 
8.5 Pathogenesis of primary IgA nephropathy 
Patients with IgAN have increased serum level of IgAl and deposits 
of IgAl in their glomerular mesangium. The origin of the IgAl deposit 
is unknown. Two contrasting hypotheses have been proposed: (1) 
Accumulating evidences suggest that the bone marrow is the production 
site of the IgA deposits due to a significant increase of the percentage of 
plasma cells containing IgA, especially the IgAl subclass, in the bone 
marrow of IgAN patients (116, 117). Furthermore, there is increased 
production of IgAl as compared to the total IgA synthesis (116). (2) 
Frequent observation of synpharyngitic macroscopic haematuria, 
provides evidence of the mucosal origin of IgA nephropathy. According-
,ly, some authors proposed that mucosal IgA, possibly produced as a 
response to antigenic stimuli, reaches the vascular compartment and 
subsequently forms mesangial deposits of IgA and complement factor 
(118-120). 
Although mucosal abnormalities have so far only been found in the 
tonsils, the relationship of these abnormalities to the above-mentioned 
phenomena in the circulation is unclear. The second hypothesis, however, 
discounts the well established fact that in healthy individuals serum IgA is 
not produced in the mucosal tissue, but mainly in the bone marrow. 
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Other findings that tend to refute the role of mucosal IgA in the 
mesangial IgA deposit include: (1) some patients have tonsillectomy 
before the first manifestation of the renal disease, (2) failure to demon-
strate any significant difference in intestinal mucosa between patients 
and healthy controls (121)，and (3) lack of evidence of the mucosal 
immune system and bronchus associated lymphoid tissues contributing to 
the circulating pool of IgA (122). These findings suggest that the bone 
marrow may well be the site of long-term overproduction of IgAl found 
in the circulation and mesangial deposits in IgA nephropathy. 
8.6 Interaction between circulatory IgA and fibronectin (FN) in primary 
IgAN 
A brief overview of structure, function, and physiology of 
fibronectin was presented by R.A. Proctor (123). Fibronectin is a high 
molecular weight glycoprotein (440-500 kDa) that can exist in a soluble 
form as that found in plasma and other extracellular body fluids, or as an 
insoluble form in extracellular matrix. Structurally, it is composed of 
blocks of three types of repeating, homologous peptide sequences. 
Several of the homologous blocks form functional domains that are 
organized in a linear array on two nearly identical subunits (Fig.3) 
Specific domains allow fibronectin to promote cell-to-cell adhesion, cell-
to-basement-membrane attachment, clot stabilization, embryogenesis, 
nerve regeneration, fibroblast migration, macrophage functions, and 
pathogen (virus, bacteria, and protozoa) binding to mammalian cells and 
extracellular matrix (Fig.3). Thus, this complex and multifunctional 























































































































































































































































































































































There are growing evidence suggesting that FN plays an important 
role in the pathogenic process in some forms of immune complex medi-
ated glomerulonephritis (124，125-128). The IgA-FN aggregate is found 
to be elevated in the circulation of patients with IgAN (109，110，125, 
128). FN (secreted by glomerular mesangial cells) present in the kidney is 
a normal component of mesangium, locating particularly along the 
processes of the mesangial cells and on the interface between the 
mesangium and the capillary endothelium (126). Some authors have 
suggested the IgA-FN aggregate is involved in the pathogenesis of IgAN 
(128) and serum IgA-FN may be of values in IgAN but data seen to 
contradict such view (110). 
The binding between IgA and FN is mediated by the Fc region that 
interacts with a yet unidentified site of the fibronectin molecule other than 
its heparin-binding and collagen-bind domains (109，110). The binding 
capacity of secretory and polymeric IgA is higher than that of monomelic 
IgA. The fibronectin-IgA interaction was specific, dose-dependent, Ca2+ 
dependent, saturable, non-covalent, and was inhibited by soluble FN, and 
appeared to involve binding site other than its Clq-binding domain (110). 
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Chapter 9 
Materials and Methods 
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9.1 Design of experiment 
It is generally agreed that the mesangial IgA belongs to the subclass 
IgAl but the percentage of the mesangial IgA and the circulating immune 
complexes being polymeric remains unclear. In the present study, we 
studied this issue by using combined techniques of affinity chromatogra-
phy, gel filtration, and ELISA. 
Our experiment aim to measure (1) the distribution of monomeric 
IgA (mlgA) and polymeric IgA (plgA) in the sera of IgAN patients, (2) 
the kappa and lambda ratios of IgAl in either the mlgA or plgA fraction 
of IgAN patients, and (3) concentration of IgA immune complexes in the 
sera of IgAN patients. 
9.2 Sera 
The sera aliquoted and stored at -20°C for JBP purification were 
obtained from 30 normal subjects and 30 patients with primary IgAN. As 
BSA is used for blocking the non-specific sites in our ELISA, sera positive 
for IgA anti-BSA antibody were excluded in our study. 
9.3 Analysis of IgAl/IgA ratio in sera and JBP 
IgAl to IgA ratio of sera and JBP were analyzed to determine any 
altered binding of IgAl to jacalin in patients. Five ml jacalin-agarose was 
dispensed, 250 |nl per aliquot, to 20 polystyrene columns. Nonspecific 
binding of the gel was first blocked with 5 ml 0.1% BSA in JEB, and the 
gel was then washed and equilibrated with 10 ml JEB. Fifty (ill serum was 
diluted to 1 ml with JEB and was loaded to the column. The column was 
stopped and incubated with shaking for 30 minutes at room temperature. 
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The unbound fraction was washed with 10 ml JEB and the JBP was eluted 
with 2 ml 0.1 M melibiose in JEB. IgA and IgAl concentration in the sera 
and JBP of ten IgAN sera and ten control sera were analyzed by ELISA. 
9.4 Purification and Fast protein liquid chromatography (FPLC) of jacalin-
bound protein (JBP) 
JBP was isolated by jacalin-agarose affinity chromatography using 
Econo System (Bio-Rad). Briefly, 4 ml serum was centrifuged at 16000 
rpm for 5 minutes and diluted in 1:5 with JEB containing 20 mM sodium 
phosphate, 150 mM sodium chloride, 0.02% sodium azide, pH 7.4 and 
were loaded to 5-ml Jacalin-agarose column(Pierce Chemical Co, 20395). 
After washing with JEB until the O.D. of the effluent at 280 nm was 
below 0.01，JBP were eluted with elution buffer containing 0.1 M 
melibiose (Sigma) in JEB. The JBP was concentrated to 200 \il with 
concentrator of 30 kDa cut-off (Amicon). 
Gel filtration chromatography of JBP was performed at room 
temperature by FPLC system as described in 2.1.3. 
Based on the preliminary analysis of the IgA, slgA, and IgA-IC 
distribution in the FPLC fractions, two pools from fraction 30 to 40 
(pooled-Pl) and from fraction 41 to 49 (pooled-P2) were prepared for 
further quantitative analysis of IgA and IgA containing immune com-
plexes (IgA-IC). The pooled fractions were concentrated to 1 ml with 
concentrator and stored under -70°C until use. As IgA is the predomi-
nant JBP (1.2.6)，the protein concentrations of pooled-fractions were 
estimated according to the extinction coefficient of IgA as El%280 
92 
equals 13.2 (150). ‘ 
9.5 Analysis of FPLOfractionated JBP 
9.5.1 ELISA of IgA-containing immune complexes (IgA-IC) 
FPLC fractions of JBP from two IgAN patients and two control 
subjects were studied for the distribution of IgA-fibronectin, secretory 
IgA (slgA)，IgA-IgA, and dimeric-IgA by sandwich ELISA. Capturing 
antisera was diluted in 0.1 M carbonate-bicarbonate buffer, pH 9.6 and 
was introduced 100 卩 1 per well. For detection of IgA-fibronectin and 
slgA complexes, goat anti-human sera against fibronectin and secretory 
component (Sigma) were used as capturing antibody in dilution of 
1:3000，while monoclonal rabbit anti-human IgA (1:10000) (Dako) was 
used in IgA-IgA ELISA. For dlgA, human colostrum secretory compo-
nent (SC) was prepared as described (151，152) and used in the dilution 
of 1:500. The microtiter plates were incubated overnight at 4。C and then 
blocked with 1% BSA in phosphate buffered saline (PBS). After 
blocking, the plates were washed twice with PBS containing 0.05% 
tween-20 (PBS-tween) and FPLC fractions in appropriate dilution with 
PBS were introduced 100 (ill per well. The plates were incubated at 37。C 
for two hours and again washed three times with PBS-tween, then 100 (ill 
per well detecting antiserum, namely monoclonal rabbit anti-human IgA 
with horseradish peroxidase (HRP) conjugate (1:10000) (Dako) was 
added. After incubation in 37°C for 1 hour, the plates were washed four 
times with PBS-tween and 100 (Lil freshly prepared substrate solution 
containing 0.034% (w/v) O-phenylenediamine powder (Sigma) in 10 ml 
citrate/phosphate buffer with urea hydrogen peroxide (Sigma) was added. 
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The plates were incubated at room temperature for a further 10 minutes 
and the reaction was stopped with 100 |xl 2 M sulfuric acid. Finally, the 
reaction was terminated by addition of 50 叫 per well 1 M sulfuric acid， 
and the absorbances were measured at 490 nm using a Dynatech 
Microplate Reader. 
For detection of IgA-C3 and IgA-IgM, anti-human C3 and anti-
human IgM were used as capturing antibody and anti-human IgA with 
HRP conjugate as detecting antibody. 
9.5.2 Quantitative ELISA of IgA, K-IgAl，and 入-IgAl 
Concentrations of IgA, K-IgAl, and 入-IgAl of the FPLC 
fractionated JBP were determined by sandwich ELISA. The method was 
similar to the ELISA of IgA-IC as described previously (9.5.1). Capture 
antisera including monoclonal rabbit antisera to human IgA, IgA kappa 
light chain (Dako), and IgA lambda light chain(Dako) were used at 
1:10000，1:3000，and 1:3000 dilutions, respectively. To quantify 
concentrations of IgA, IgAl with kappa light chain (K-IgAl) and IgAl 
with lambda light chain (入-IgAl)，purified human myeloma 
immunoglobulin standards including human IgA(Nordic，Tilburg, 
Netherland), IgAl with kappa light chain (The Binding Site, Birming-
ham, UK), and IgAl with lambda light chain (The Binding Site) were 
diluted two-fold in PBS and processed in parallel with samples. Then, 
IgA, K-IgAl and 入-IgAl concentrations were determined by referring to 
their corresponding standard curves and corrected for dilution factor 
when the result was justified by selecting those absorbances fallen within 
the linear phase of the standard curve. For those out-phased batches, 
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they were repeated with appropriate dilution. Finally, the KlX light chain 
ratios of IgAl were calculated. 
9.5.3 Measurement of slgA，dlgA and IgA containing immune complex 
(IgA-IC) 
As the distribution of slgA, dlgA and IgA-IC in the FPLC fractions 
was clearly defined, plgA or IgA-IC concentrations were determined in 
different peaks of JBP after subjecting to FPLC. The quantitative 
measurement of these different fractions was achieved by sandwich 
ELISA as described previously (9.5.1). 
9.5.4 SDS-PAGE analysis 
Fractions obtained from the FPLC of JBP were also analyzed by 
SDS-PAGE (10% polyacrylamide) under either reducing or non-reducing 
condition (2.1.7). 
9.6 Statistics 
Statistical calculations were performed on a microcomputer 
(Macintosh LCIII) using a standard statistical package (Statview II， 
Brainpower, Calabasas, Calif, USA). For comparison between patient 
and control groups, the Mann-Whitney U test were adopted. The values 
of ELISA results were expressed as mean 土 standard error of mean. The 





10.1 IgAl/IgA ratio of serum and JBP 
Recovery of IgA and IgAl after passing through the jacalin column 
were 74.3士 15.1% and 69.1±14.2% (20 samples, 10 IgAN patients and 10 
control), respectively. The recovery of IgA and IgAl in IgAN sera 
(N=10) did not differ from that of control sera (N=10) (p>0.3). The 
serum IgAl/IgA ratio did not differ between patients and controls 
(0.8m 1 in IgAN patients versus 0.8±0.1 in controls; p=0.93), and this 
ratio did not change in the JBP of either IgAN patients (0.810.1) (p=0.6) 
or controls (0.810.1) (p=0.6). 
10.2 Isolation and FPLC of JBP 
Serum levels of JBP of IgAN patients were significantly higher 
than those of control subjects (1.66±0.05 mg/ml versus 1.5±0.02 mg/ml, 
P<0.02). Fig. 1.1 shows a typical FPLC profile of JBP with two major 
peaks 440 kDa (P2) and 67 kDa (P3) together with one minor peak of 
667 kDa (PI). By comparing the protein concentrations of pooled-Pl 
and pooled-P2 of IgAN patients with that of controls (Table 3.1)，the 
level of pooled-P2 was significantly increased in IgAN patients 
(p<0.0001). The protein concentration of pooled-Pl did not differ 
between IgAN patients and control subjects (p>0.2). The ratio of pooled-
Pl to pooled-P2 was lower in IgAN patients (0.11 士 0.01) than in 
) controls (0.14 土 0.01，p<0.03). 
10.3 SDS-PAGE analysis of FPLC fractionated JBP 
FPLC fractions corresponding to void volume (fraction 26), PI 





























































































































































































































































































































































































were analyzed with SDS-PAGE under non-reducing condition (Fig. 
3.1a). The banding pattern revealed that PI contained predominantly of 
high molecular weight (MW) (>200 kDa) complex, P2 contained 
heterogeneous proteins of MW ranged from 149 to 177 kDa, and P3 
contained mainly of a 55 kDa protein which was identified as a2HSG 
(see part I). Under reducing condition, both PI and P2 proteins were 
broken down to heavy chain (55 kDa) and light chain (29 kDa) of IgA 
(Fig.3.1b). 
10.4 ELISA of the FPLC fractionated JBP 
10.4.1 Distribution of IgA, secretory IgA (slgA) and dimeric IgA (dlgA) 
in the FPLC fractions 
The distribution of IgA, slgA or dlgA in the FPLC fractioned JBP 
is shown in Fig.3.2. IgA was detected mainly in pooled-Pl and pooled-
P2 (Fig.3.2b). slgA and dlgA were found mainly in pooled-Pl and 
pooled-P2 (Fig.3.2c and 3.2d). The profiles of IgAl and slgAl distribu-
tion are concerned were similar to those of IgA and slgA (Fig.3.2b and 
3.2c). 
10.4.2 Distribution of IgA containing immune complex (IgA-IC) in the 
FPLC fractions 
IgA-fibronectin (IgA-FN), IgA-C3, IgA-IgG and IgA-IgM were 
present in FPLC fractionated JBP from either IgAN patients (N=2) or 
control subjects (N=2) (Fig.3.3). IgA-FN showed a diffuse distribution 
in pooled-Pl and pooled-P2 (Fig.3.3b) whereas IgA-IgG and IgA-C3 
were found exclusively in pooled-Pl. IgA-IgM was only detected in the 
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Fig.3.1 SDS-PAGE (10% polyacrylamide) of FPLC fractionated 
JBP. (a) non-reducing gel. (b) reducing gel. Fraction 
numbers 26，31-37，41-46，and 50-51 represent the void 
volume, PI (polymeric IgA), P2 (monomeric IgA) and P3 












































































































































































































Fig.3.2 Distribution of IgA, slgA, and IgA that is capable of 
binding secretory component (SC) in the FPLC 
fractionated JBP. (a) FPLC profile of JBP. (b) ELISA 
profile of IgA and IgAl in the FPLC fractions. (c)ELISA 
profile slgA and slgAl in the FPLC fractions, (d) ELISA 
profile of IgA that is capable of binding SC. 
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Fig.3.3 Distribution of IgA-IC in the FPLC fractionated JBP. 
(a) FPLC profile of JBP. (b) ELISA profile of IgA-FN. (c) 
ELISA profile of of IgA-IgG. (d) ELISA profile of IgA-
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void volume eluate. 
10.4.3 Quantitation of IgA 
The concentration of IgA in the pooled-Pl and pooled-P2 is 
presented in Fig.3.4. Briefly, pooled-Pl and pooled-P2 from IgAN 
patients were significantly increased when compared with that from 
normal controls (p<0.003 and p<0.05，respectively). 55.4% of patients 
had elevated serum IgA defined by level > mean of serum IgA level 
from controls plus one standard deviation. Similarly, 46.7% and 56.7% 
of patients had increased IgA level in pooled-Pl and pooled-P2, respect-
ively. 
Studies of IgA in the FPLC fractions showed that: (1) pooled-Pl 
contained 8.3±1.7% of total IgA for controls and 7.9±1.30% for IgAN 
patients (p>0.8)，(2) pooled-P2 contains 85.1+2.3% of total IgA for. 
controls and 84.2±2.2% for IgAN patients (p>0.8). 
10.4.4 Quantitation of K-IgAl and 入-IgAl, and determination of k/X 
ratio of IgAl 
The K-IgAl and 入-IgAl concentrations of the pooled peak frac-
tions (pooled-Pl and pooled-P2) are shown in Fig.3.5. IgAN patients 
had significant elevation of K-IgAl and X-IgAl concentrations for 
pooled-P2 when compared with normal subjects (1.6 土 0.08 versus 1.2 土 
0.11 mg/ml, p<0.03, and 1.0 士 0.06 versus 0.7 士 0.08 mg/ml, p<0.01) 
(Fig.3.5a and 3.5b). The K-IgAl and 入-IgAl levels of sera were also 
significantly increased in IgAN patients (p<0.0001). As the total IgAl 
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Fig.3.5 K-IgAl and 人-IgAl of the pooled FPLC peak 
fractions. Vertical bars indicate the SEM. 
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concentrations, IgAN patients had shown significant increase of IgAl 
level for the pooled-P2 when compared with the controls (2.25±0.09 
mg/ml for IgAN versus 1.7310.12 mg/ml for controls, p<0.0001) • 
Nevertheless, the IgAl level of pooled-Pl remains unchanged for IgAN 
patients (0.18±0.02 mg/ml) as compared with controls (0.16土0.02 
mg/ml) (p>0.5). 
As for the K/X ratio, IgAN patients had significant decrease of the 
ratio for both pooled-Pl and pooled-P2 when compared with the control 
subjects (p<0.01) (Fig.3.6). 
10.4.5 Quantitation of slgA, dlgA, and IgA-containing immune complex 
(IgA-IC) 
slgA，IgA-C3, and IgA-IgG were found to distribute exclusively in 
pooled-Pl, and hence, quantitative measurement of their levels were 
focused on pooled-Pl (Table 3.2). There was no significant increase of 
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In the present study, we adopted jacalin-agarose affinity chromatog-
raphy for isolation of JBP, which allowed the isolation of IgA and IgA-
IC. It is now clear that the abnormalities in the IgA system of patients 
with IgAN appear to be limited only to IgAl (section 8.2). As IgAl is 
known to interact selectively with jacalin (section 1.2.5)，this unique 
property allowed us to isolate the serum IgAl for analysis. The previous 
experiments by Chui et al. (129) had shown that the IgAl/IgA ratio was 
not changed after recovery of JBP from control sera, and the ratio from 
sera was not different between in IgAN patients and controls (87). In the 
present experiment, we further confirmed that the ratio was not changed 
in the JBP from IgAN patients suggesting the interaction of IgAl to 
jacalin is not altered in IgAN patients. 
By using FPLC, different components of JBP were isolated, which 
allowed not only the separation of IgA from non-IgA JBP (fraction 52 to 
55) (part I) but also the polymeric IgA (plgA) from the monomeric IgA 
(mlgA). The "following evidences suggest that PI and P2 corresponding 
to pig A and mlgA respectively: (1) As the JBP was passed through an 
anti-human IgA conjugated Sepharose 4B affinity column, PI and P2 
were retained in the column, suggesting that these fractions contained 
exclusively either IgA or IgA-containing immune complexes (part I). 
Their MW were 667 kDa (PI) and 440 kDa (P2). The latter peak is far 
larger than the expected MW of mlgA (160 kDa) and this may due to the 
incorrect estimation of MW by gel filtration. Nevertheless, these two 
well separated peak fractions are, in all likelihood, to encompass the high 
MW and low MW IgA. (2) By SDS-PAGE, P2 was demonstrated to 
contain predominantly of mlgA (160 kDa) with trace amount of Cl-INH. 
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(3) By using ELISA, macromolecular IgA such as slgA, IgA-C3, IgA-
IgG，IgA-FN were shown to distribute mainly in pooled-Pl. Accordingly, 
our approach provides a fast and convenient method for separation of 
pig A from mlgA when compared with those reported by others (98，100， 
130-132). The relative quantity of macromolecular IgA to mlgA can be 
measured directly from the total protein concentration of PI over P2. In 
fact，pooled-Pl and pooled-P2 from controls constitute 88.1 ±2.2% and 
11.9±3.3% (N=30) of total IgA and these percentages are in agreement 
with the normal distribution of mlgA (90-95%) and pIgA(0,5-12%) in 
the human circulation (133,134). 
The IgA concentrations of pooled-Pl and pooled-P2 suggest that 
both pooled-P2 (mlgA) and pooled-Pl (macromolecular IgA) were 
increased in IgAN patients (p<0.003 and p<0.05, respectively). Indeed, 
the IgAl level of IgAN patients were also elevated significantly for the 
pooled,P2 when compared with the controls (P<0.0001). These results 
strongly suggested that IgAN patients had a higher content of mlgA, 
especially the IgAl subclass, in the circulation as reported previously 
(114). Interestingly, the percentage of IgA or IgAl in pooled-Pl and 
pooled-P2 remains unchanged for both IgAN patients and controls, this 
suggests that the increase of mlgA may be accompanied by an increase in 
pig A of similar magnitude. In fact, similar findings have been reported 
previously (135，148). 
Previous reports have demonstrated the reversed K/A, ratio in both 
the serum and mesangial IgA deposit of IgAN patients (88). We further 
examined whether the selective overproduction of 入-IgA is occurred to 
mlgA or plgA population. It is now agreed that IgAl plays an important 
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role in the pathogenesis of IgAN and therefore it is reasonable to focus 
our attention on this subclass when k/X ratio is concerned. As the 
binding of jacalin to IgA2 is still controversial (section 1.2.5), we 
arbitrarily assumed the exclusive presence of IgAl in the JBP. Accord-
ingly, we have demonstrated that the k/X ratio of both plgA and mlgA 
was significantly reduced in IgAN patients when compared with controls 
(p<0.01). This finding again indicated that bone marrow may play an 
important role in the pathogenesis of IgAN. Mesangial IgA deposits are 
capable to bind SC in the presence of J-chain, indicating that at least part 
of these IgA is polymeric (76，89, 90，91, 92). However, there is still 
considerable disagreement on the relative importance of the polymeric 
IgA as the immunofluorescence technique is incapable of assessing the 
relative contribution of polymeric IgA to the total IgA present in the 
deposits (86, 92). van den Wall Bake et al. (116) had suggested that bone 
marrow derived mlgAl is also deposited in mesangium. We demon-
strated that the circulatory plgA of IgAN patient has the reversed kJX 
ratio in agreement with that observed in the mesangial IgA deposits (88). 
This finding may suggest that the circulatory plgA is also deposited in 
glomerular mesangium. 
Early studies reported elevation of circulatory IgA-IC level in IgAN 
patients, such as plgA (98-100，134，136)，IgA-IgG (55，137), IgA-FN 
(67，125，128)，IgA-C3, and IgA-rheumatoid factor (111-114). Methods 
devised for the detection of immune complexes rely mostly on the 
ability of soluble immune complexes to bind Clq or the attachment of 
complexes to specific cellular receptors, such as C3 receptors on Raji 
cells, or Fc receptors on macrophages or platelets (149). Some tests 
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utilize the ability of monoclonal rheumatoid factor or staphylococcal 
protein A to bind preferentially the Fc portion of IgG in immune com-
plexes (139). All methods that are designed for detecting the IgG 
associated immune complexes are found unsuitable for detection of the 
IgA-IC. The prevalence of IgA-IC in these studies was highly variable: 
between 9% and 69% of the patients when less ideal methods (98，100， 
140) were used. Methods used for detection of IgA-IC rely on the PEG 
fractionation of the serum followed by the ability of polymeric IgA to 
bind secretory component (SC) (133，141) or anti-IgA inhibition assay 
(131). As precipitation by PEG is non-specific and it is difficult to 
optimize the condition for separation of macromolecular IgA from mlgA, 
this often results in overestimating the true value of IgA-IC. Further-
more, the presence of mlgA exerts inhibitory effect on the anti-IgA 
inhibition assay, and may also underestimate the IgA-IC level when part 
of the IgA-IC is precipitated. Moreover, we have shown in the present 
study that IgA capable to bind SC (dlgA) is not in the form of IgA-IC as 
the majority of dlgA is distributed in pooled-P2 but not in pooled-Pl 
(Fig.3.2d). 
The present method is appropriate for quantitative measurement of 
the macromolecular IgA as the pooled-Pl can be separated from all other 
serum proteins (unbound fraction of jacalin affinity column) and the 
mlgA (pooled-P2). In the present study, we demonstrated that the 
macromolecular IgA is elevated slightly in the IgAN patients (P<0.05)， 
but analysis of the individual IgA-IC did not show difference between 
IgAN patients and controls. The serum level of IgA-FN in IgAN patients 
was not elevated as compared with the controls. Similar finding had also 
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been reported by Davin et al. (110) and other report also suggested that 
the circulatory IgA-IC can only be detected during macroscopic 
haematuria (134). 
Previous reports had described the use of sucrose density-gradient 
ultracentrifugation for separation of macromolecular IgA from mlgA 
(98)，yet, the extreme acidic pH (2.8) may affect the native composition 
of the true IgA-IC. In contrast to their extreme buffering condition, the 
present protocol adopts a better buffering condition as all experimental 
procedures are performed under physiological pH (7.4) and buffered by 
isotonic solution (PBS). Hence, the macromolecular IgA can be obtained 
in their native form. Practically, this technique is appropriate for 
purification of native IgA-IC for laboratory study. 
The major problems of adopting the presently described method 
include: (1) It is not practical to adopt this method for routine diagnosis 
due to time consuming procedures are involved. (2) Theoretically, this 
method may be appropriate for purification of IgAl as IgA2 does not 
contain the carbohydrate units in the hinge region. 
; : 117 
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